Zacks Small Cap Research on MSN13h
CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.
CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, ...
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of ...